injectable filler

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced that the US Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA).

Shares of obesity drug developers rose Thursday following a report that Arena Pharmaceuticals Inc.’s lorcaserin prompted weight loss without heart-related side effects.On Wednesday, a study showed that lorcaserin caused more people to lose at least 5 percent of their body weight over one year, or more than double the rate of placebo.